WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access

The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited production of Regeneron Pharmaceuticals Inc's REGN antibody combination.
Related Content: WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients.
The treatment, called Ronapreve, or REGEN-COV, includes casirivimab and imdevimab.
UNITAID is negotiating with Roche Holdings AG RHHBY, which is currently manufacturing the drug, for lower prices and equitable distribution.
The agency also urged the firms to transfer tech to help make biosimilars.
Read Next: FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis.
Recently, the U.S. ordered additional 1.4 doses of REGEN-COV by January 31.
Related Link: U.S. Govt Calls For Additional Doses Of Regeneron's COVID-19 Antibody Therapy.
Price Action: REGN stock is down 1.86% at $634.47, and RHHBY stock is down 1.11% at $45.91 during the market session on the last check Friday.